Value of an Integrated Home Dialysis Model in the United Kingdom: A Cost-Effectiveness Analysis

被引:5
作者
Erbe, Amanda W. [1 ,4 ]
Kendzia, Dana [2 ]
Busink, Ellen [2 ]
Carroll, Suzanne [3 ]
Aas, Eline [1 ]
机构
[1] Univ Oslo, Dept Hlth Management & Hlth Econ, Oslo, Norway
[2] Fresenius Med Care, Market Access & Hlth Econ, Bad Homburg, Germany
[3] Fresenius Med Care UK Ltd, Hlth Econ, Market Access & Prod Management, Huthwaite, England
[4] Univ Oslo, Dept Hlth Management & Hlth Econ, POB 1089 Blindern, Oslo 0317, Norway
关键词
economic evaluation; home hemodialysis; home -to -home transition; patient pathway management; peritoneal; dialysis; renal replacement therapy; QUALITY-OF-LIFE; PERITONEAL-DIALYSIS; HEMODIALYSIS; DISEASE; UTILITY; RISK;
D O I
10.1016/j.jval.2023.02.009
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objectives: This study aimed to determine the lifetime cost-effectiveness of increasing home hemodialysis as a treatment option for patients experiencing peritoneal dialysis technique failure compared with the current standard of care.Methods: A Markov model was developed to assess the lifetime costs, quality-adjusted life-years, and cost-effectiveness of increasing the usage an integrated home dialysis model compared with the current patient pathways in the United Kingdom. A secondary analysis was conducted including only the cost difference in treatments, minimizing the impact of the high cost of dialysis during life-years gained. Sensitivity and scenario analyses were performed, including analyses from a societal rather than a National Health Service perspective.Results: The base-case probabilistic analysis was associated with incremental costs of & POUND;3413 and a quality-adjusted life-year of 0.09, resulting in an incremental cost-effectiveness ratio of & POUND;36341. The secondary analysis found the integrated home dialysis model to be dominant. Conclusions on cost-effectiveness did not change under the societal perspective in eitherConclusions: The base-case analysis found that an integrated home dialysis model compared with current patient pathways is likely not cost-effective. These results were primarily driven by the high baseline costs of dialysis during life-years gained by patients receiving home hemodialysis. When excluding baseline dialysis-related treatment costs, the integrated home dialysis model was dominant. New strategies in kidney care patient pathway management should be explored because, under the assumption that dialysis should be funded, the results provide cost-effectiveness evidence for an integrated home dialysis model.
引用
收藏
页码:984 / 994
页数:11
相关论文
共 50 条
  • [31] Cost-effectiveness of enhanced external counterpulsation (EECP) for the treatment of stable angina in the United Kingdom
    McKenna, Claire
    Hawkins, Neil
    Claxton, Karl
    McDaid, Catriona
    Suekarran, Sara
    Light, Kate
    Chester, Michael
    Cleland, John G. F.
    Woolacott, Nerys
    Sculpher, Mark
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2010, 26 (02) : 175 - 182
  • [32] Evaluation of the cost-effectiveness of rifaximin-α for the management of patients with hepatic encephalopathy in the United Kingdom
    Berni, Ellen
    Murphy, Daniel
    Whitehouse, James
    Conway, Pete
    di Maggio, Paola
    Currie, Craig J.
    Poole, Chris
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (11) : 2001 - 2008
  • [33] Cost-effectiveness analysis: adding value to assessment of animal health, welfare and production
    Martins, S. Babo
    Rushton, J.
    REVUE SCIENTIFIQUE ET TECHNIQUE-OFFICE INTERNATIONAL DES EPIZOOTIES, 2014, 33 (03): : 681 - 689
  • [34] Cost-effectiveness and value of information analysis of multiple frequency bioimpedance devices for fluid management in people with chronic kidney disease having dialysis
    Jacobsen, Elisabet
    Cruickshank, Moira
    Cooper, David
    Marks, Angharad
    Brazzelli, Miriam
    Scotland, Graham
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2021, 19 (01)
  • [35] Predicting Mortality in Incident Dialysis Patients: An Analysis of the United Kingdom Renal Registry
    Wagner, Martin
    Ansell, David
    Kent, David M.
    Griffith, John L.
    Naimark, David
    Wanner, Christoph
    Tangri, Navdeep
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2011, 57 (06) : 894 - 902
  • [36] The Value of Health in a Cost-Effectiveness Analysis: Theory Versus Practice
    Wouterse, Bram
    van Baal, Pieter
    Versteegh, Matthijs
    Brouwer, Werner
    PHARMACOECONOMICS, 2023, 41 (06) : 607 - 617
  • [37] A Modeling Study of the Cost-Effectiveness of a Risk-Stratified Surveillance Program for Melanoma in the United Kingdom
    Wilson, Edward C. F.
    Usher-Smith, Juliet A.
    Emery, Jon
    Corrie, Pippa
    Walter, Fiona M.
    VALUE IN HEALTH, 2018, 21 (06) : 658 - 668
  • [38] The Core Value of Cost-Effectiveness Analyses
    Dhruva, Sanket S.
    Krumholz, Harlan M.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (01) : 39 - 41
  • [39] Modeling the Cost-Effectiveness of Prothrombin Complex Concentrate Compared With Fresh Frozen Plasma in Emergency Warfarin Reversal in the United Kingdom
    Guest, Julian F.
    Watson, Henry G.
    Limaye, Sameer
    CLINICAL THERAPEUTICS, 2010, 32 (14) : 2478 - 2493
  • [40] Strengthening health systems to improve the value of tuberculosis diagnostics in South Africa: A cost and cost-effectiveness analysis
    Foster, Nicola
    Cunnama, Lucy
    McCarthy, Kerrigan
    Ramma, Lebogang
    Siapka, Mariana
    Sinanovic, Edina
    Churchyard, Gavin
    Fielding, Katherine
    Grant, Alison D.
    Cleary, Susan
    PLOS ONE, 2021, 16 (05):